Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of disease or on progression and to obtaining additional predictive information on i...

Descripción completa

Detalles Bibliográficos
Autores: Remon, Jordi, García-Campelo, Rosario, Álava, Enrique de, Rodríguez-Peralto, José Luis, Rodríguez-Lescure, Álvaro, Bellosillo, Beatriz, Garrido, Pilar, Álvarez-Alegret, Ramiro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/235733
Acceso en línea:http://hdl.handle.net/10261/235733
Access Level:acceso abierto
Palabra clave:Liquid biopsy
ctDNA
Oncology
Genomic profiling
Precision medicine
id ES_dbbe50d3280e4e3470ae4355788a6727
oai_identifier_str oai:digital.csic.es:10261/235733
network_acronym_str ES
network_name_str España
repository_id_str
spelling Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyRemon, JordiGarcía-Campelo, RosarioÁlava, Enrique deRodríguez-Peralto, José LuisRodríguez-Lescure, ÁlvaroBellosillo, BeatrizGarrido, PilarÁlvarez-Alegret, RamiroLiquid biopsyctDNAOncologyGenomic profilingPrecision medicineThe proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of disease or on progression and to obtaining additional predictive information on immunotherapy efficacy. However, in up to 25% of cases, the initial tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not possible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alternatives are therefore required for molecular stratification, which includes liquid biopsy. This technique enables the evaluation of the tumour genomic profile dynamically and captures intra-patient genomic heterogeneity as well. To date, there are several diagnostic techniques available for use in liquid biopsy, each one of them with different precision and performance levels. The objective of this consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology is to evaluate the viability and effectiveness of the different methodological approaches in liquid biopsy in cancer patients and the potential application of this method to current clinical practice. The experts contributing to this consensus statement agree that, according to current evidence, liquid biopsy is an acceptable alternative to tumour tissue biopsy for the study of biomarkers in various clinical settings. It is therefore important to standardise pre-analytical and analytical procedures, to ensure reproducibility and generate structured and accessible clinical reports. It is essential to appoint multidisciplinary tumour molecular boards to oversee these processes and to enable the most suitable therapeutic decisions for each patient according to the genomic profile.SEAP and SEOM declare that there has not been any external financial support for this project.Springer NatureSociedad Española de Anatomía PatológicaSociedad Española de Oncología MédicaConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2021202120202021info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/235733reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésD. Enko & G. Kriegshäuser (2021). Letter to the Editor regarding “Liquid biopsy in oncology: a consensus statement of the Spanish society of pathology and the Spanish society of medical oncology”. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-020-02527-zRemon, J.; García-Campelo, R.; Álava, Enrique de ; Rodríguez-Peralto, J. L.; Rodríguez-Lescure, A.; Bellosillo, B.; Garrido, Pilar; Álvarez-Alegret, R. (2020). Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-020-02313-x . http://hdl.handle.net/10261/235734http://doi.org/10.1007/s12094-019-02211-xSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2357332026-05-22T06:33:51Z
dc.title.none.fl_str_mv Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
title Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
spellingShingle Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Remon, Jordi
Liquid biopsy
ctDNA
Oncology
Genomic profiling
Precision medicine
title_short Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
title_full Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
title_fullStr Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
title_full_unstemmed Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
title_sort Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
dc.creator.none.fl_str_mv Remon, Jordi
García-Campelo, Rosario
Álava, Enrique de
Rodríguez-Peralto, José Luis
Rodríguez-Lescure, Álvaro
Bellosillo, Beatriz
Garrido, Pilar
Álvarez-Alegret, Ramiro
author Remon, Jordi
author_facet Remon, Jordi
García-Campelo, Rosario
Álava, Enrique de
Rodríguez-Peralto, José Luis
Rodríguez-Lescure, Álvaro
Bellosillo, Beatriz
Garrido, Pilar
Álvarez-Alegret, Ramiro
author_role author
author2 García-Campelo, Rosario
Álava, Enrique de
Rodríguez-Peralto, José Luis
Rodríguez-Lescure, Álvaro
Bellosillo, Beatriz
Garrido, Pilar
Álvarez-Alegret, Ramiro
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sociedad Española de Anatomía Patológica
Sociedad Española de Oncología Médica
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Liquid biopsy
ctDNA
Oncology
Genomic profiling
Precision medicine
topic Liquid biopsy
ctDNA
Oncology
Genomic profiling
Precision medicine
description The proportion of cancer patients with tumours that harbour a potentially targetable genomic alteration is growing considerably. The diagnosis of these genomic alterations can lead to tailored treatment at the onset of disease or on progression and to obtaining additional predictive information on immunotherapy efficacy. However, in up to 25% of cases, the initial tissue biopsy is inadequate for precision oncology and, in many cases, tumour genomic profiling at progression is not possible due to technical limitations of obtaining new tumour tissue specimens. Efficient diagnostic alternatives are therefore required for molecular stratification, which includes liquid biopsy. This technique enables the evaluation of the tumour genomic profile dynamically and captures intra-patient genomic heterogeneity as well. To date, there are several diagnostic techniques available for use in liquid biopsy, each one of them with different precision and performance levels. The objective of this consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology is to evaluate the viability and effectiveness of the different methodological approaches in liquid biopsy in cancer patients and the potential application of this method to current clinical practice. The experts contributing to this consensus statement agree that, according to current evidence, liquid biopsy is an acceptable alternative to tumour tissue biopsy for the study of biomarkers in various clinical settings. It is therefore important to standardise pre-analytical and analytical procedures, to ensure reproducibility and generate structured and accessible clinical reports. It is essential to appoint multidisciplinary tumour molecular boards to oversee these processes and to enable the most suitable therapeutic decisions for each patient according to the genomic profile.
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/235733
url http://hdl.handle.net/10261/235733
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv D. Enko & G. Kriegshäuser (2021). Letter to the Editor regarding “Liquid biopsy in oncology: a consensus statement of the Spanish society of pathology and the Spanish society of medical oncology”. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-020-02527-z
Remon, J.; García-Campelo, R.; Álava, Enrique de ; Rodríguez-Peralto, J. L.; Rodríguez-Lescure, A.; Bellosillo, B.; Garrido, Pilar; Álvarez-Alegret, R. (2020). Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-020-02313-x . http://hdl.handle.net/10261/235734
http://doi.org/10.1007/s12094-019-02211-x
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer Nature
publisher.none.fl_str_mv Springer Nature
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421704158117888
score 15.81155

Similares en LA Referencia